酵母细胞壁介导的Ileal向输送系统用于IgA脏病治疗治疗
Chaoying Tian1, Mei Yan1, Jialing Guo1
1School of Pharmaceutical Sciences, Zhengzhou University, 100 Science Road, Zhengzhou, Henan 450001, China.
ACS biomaterials science & engineering
|February 17, 2025
概括
一种新的口服药物输送系统针对大肠来治疗IgA脏病 (IgAN). 该系统减少IgA的产生和炎症,为IgAN患者提供免疫治疗的新平台.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- IgA病 (IgAN) 是一种由肠轴驱动的自身免疫性病.
- 皮埃尔斑块是IgA生产的关键部位,影响IgAN的致病性.
研究的目的:
- 开发一种口服药物输送系统,用于IGAN中向的叶输送.
- 为了评估通过该系统提供的氧化 (HCQ) 和甲 (DXM) 的疗效.
主要方法:
- 构建了一种酵母细胞壁 (YCW) 涂层的油酸移植奇托 (CSO) 载体 (HCQ/DXM@CSO@YCW).
- 评估了胃肠道稳定性,生物相容性和叶向性质.
- 在IgAN小鼠中进行了体外细胞和体内生物的药学动力学研究.
主要成果:
- 该HCQ/DXM@CSO@YCW系统证明了叶向和良好的生物相容性.
- 实验室研究证实了免疫细胞的向吸收.
- 在体内研究显示,Igan小鼠的血清IgA,脏IgA沉积和炎症标志物 (IL-6,TNF-α,TGF-β) 降低,改善了病理.
结论:
- 这种YCW涂层的口服输送系统有助于针对IgA脏病的向免疫治疗.
- 这个平台显示了通过调节肠轴和减少免疫沉积来治疗Igan的潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
110
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
110
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
135
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
135
Inflammatory Bowel Disease IV: Pharmacological Management
95
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
95


